Icagen being Phase II trial of Senicapoc in Allergic Asthma

Icagen have initiated a Phase II clinical trial of KCa3.1 potassium ion channel blocker senicapoc in patients with allergic asthma.

Senicapoc blocks KCa3.1 currents in mast cells

Data presented at the 15th International Inflammation Research Association Conference show Icagen’s KCa3.1 potassium ion channel inhibitor senicapoc to potently block KCa3.1 potassium currents in isolated human lung mast cells and reduce the migration of these cells when exposed to an inflammatory stimulus.

Icagen completes Phase I trial of KCa3.1 potassium ion channel senicapoc

Icagen have completed a Phase I  trial of KCa3.1 potassium ion channel senicapoc which has potential in the treatment of asthma. The drug was well tolerated at all doses tested and in preliminary analyses